MarginsXMarginsX
Home › Markets › Health Care › CGON

CG Oncology Inc. (CGON)

CGON trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$84.78
+13.95% on the day
Market cap
$7.6B
Mid cap
Revenue · 2025
$4.0M
+254.7% on 2024
Net income · 2025
-$161.0M
-3985.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/0001193125-26-079498-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCGON on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2024
SEC CIK0001991792
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$4.0M
Net income-$161.0M
Operating income-$190.8M
Net margin-3985.0%
Operating margin-4722.1%
Revenue growth+254.7%
Cash$32.5M
Total assets$791.6M
P/E (computed)Net income was not positive
P/S (computed)1874.4×

Warning signs

Cash runway
1.8 months
$28.2M cash at September 30, 2026
Share count, 1 year
+10.7%
2025-11-12 to 2026-11-04
Going-concern doubt
No
10-Q filed November 6, 2026
Insider net buying, 12 months
$19.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-06
Cash and burn$28.2M cash; operating cash flow -$46.8M a quarter.Report 2026-09-30
Shares outstanding89,318,916 (2026-11-04); 80,666,179 a year earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-08-06
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Irvine, California, United StatesPCAOB Form AP 2026-03-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $24.8M, sold $5.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.6M-$56.9M-$47.7M$28.2M$3.0M$6.2M10-Q 2026-11-06
Q2 2026
2026-06-30
$1.2M-$79.1M-$46.4M$19.6M$3.0M$6.2M10-Q 2026-08-06
Q1 2026
2026-03-31
$1.1M-$60.2M-$56.9M$33.7M$3.0M$5.1M10-Q 2026-05-08
Q4 2025
2025-12-31
$2.3M-$41.3M-$36.2M$32.5M$3.0M$4.0M10-K 2026-02-27
Q3 2025
2025-09-30
$1.7M-$43.8M-$38.9M$45.1M$3.0M$2.2M10-Q 2026-11-06
Q2 2025
2025-06-30
$0-$41.4M-$28.0M$14.6MNo debt tags$551K10-Q 2026-08-06
Q1 2025
2025-03-31
$52K-$34.5M-$29.3M$41.5MNo debt tags$662K10-Q 2026-05-08
Q4 2024
2024-12-31
$456K-$31.8M-$20.7M$257.1M$0$1.1M10-K 2026-02-27

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-06
Latest annual report10-K2026-02-27
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 246 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-2.1%
1 month+19.2%
3 months-0.4%
Year to date+79.2%
1 year+97.0%
From 52-week high-7.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
TWSTTwist Bioscience Corporation$105.04-5.88%$7.0B
IMVTImmunovant Inc.$33.28-2.63%$6.9B
KODKodiak Sciences Inc$100.73-9.41%$6.6B
KRYSKrystal Biotech Inc.$297.90-2.40%$8.8B
IBRXImmunityBio Inc.$5.98-0.66%$6.4B
PCVXVaxcyte Inc.$61.61-2.78%$9.8B
QGENQiagen N.V. Common Shares$49.81-0.16%$10.3B
RGENRepligen Corporation$162.78-2.99%$10.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier